Pulmonx Corporation LUNG

Company Overview

Pulmonx Corporation is a medical technology company focused on developing and commercializing minimally invasive treatments for severe pulmonary diseases, primarily emphysema, a form of chronic obstructive pulmonary disease (COPD). The company operates within the medical devices and interventional pulmonology industries, targeting patients who remain symptomatic despite optimal medical therapy. Pulmonx’s core value proposition is offering less invasive alternatives to lung volume reduction surgery, aiming to improve lung function, exercise capacity, and quality of life.

The company’s primary revenue driver is its proprietary Zephyr Endobronchial Valve system, which is designed to occlude diseased portions of the lung to reduce hyperinflation. Pulmonx primarily serves hospitals and specialized pulmonary centers, with a customer base consisting of interventional pulmonologists and thoracic specialists. Founded in 1998, Pulmonx spent many years in clinical development and regulatory validation, culminating in U.S. FDA approval for the Zephyr Valve in 2018 and its initial public offering in 2020, which expanded its commercial and clinical footprint.